The Relationship of Histopathological Features of the Fallopic Tubes with the Expression of P53 Mrna and YY1 Mrna in Mucinous Ovarian Carcinoma
Main Article Content
Abstract
Introduction: Ovarian cancer is the third most common cancer in Indonesia after breast cancer and cervical cancer. The global prevalence of mucinous ovarian carcinoma is lower than other subtypes, but the relative frequency of the mucinous subtype in Indonesia is the third highest after Singapore and South Korea. Ovarian cancer develops in the tubal fimbria before metastasizing to the ovaries. Genes involved in the carcinogenesis of mucinous ovarian carcinoma include KRAS, BRAF, p53. The expression of YY1 (Yin Yang 1) is associated with increased survival in ovarian cancer patients.
Objective: The aim of this study was to determine the relationship between histopathological features of the fallopian tubes and the expression of p53 mRNA and YY1 mRNA.
Methods: This study used a cross sectional research design. The sampling technique used was purposive sampling. The sample for this study were 27 mucinous ovarian carcinoma patients at Regional General Hospital Prof. Dr. Margono Soekarjo Purwokerto. Examination of p53 and YY1 expression using qPCR and tubal histopathology using hematoxylin eosin staining.
Results: . Of the 27 study samples, 24 patients had high p53 mRNA expression and 3 patients had low p53 mRNA expression. Meanwhile, 24 patients had low expression of YY1 mRNA expression, 3 patients had high expression. Based on the results of the Fisher's Exact statistical test analysis, there was no relationship between tubal histopathological features and p53 mRNA expression in mucinous ovarian carcinoma patients, with a significance value (p) of 0.231. There was no relationship between tubal histopathological features and YY1 mRNA expression with a significance value (p) of 0.569.
Conclusion: There is no relationship between the histopathological features of the fallopian tubes and the expression of p53 mRNA and YY1 mRNA
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. GLOBOCAN. Ovarian Cancer Incidence and Mortality. Int Agency Res Cancer GLOBOCAN [Internet]. 2020;5–6. Available from:
https://gco.iarc.fr/today/data/factsheets/cancers/25-Ovary-fact-sheet.pdf
II. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9–32.
III. Shih IM, Kurman RJ. Ovarian Tumorigenesis: A Proposed Model Based on Morphological and Molecular Genetic Analysis. Am J Pathol. 2004;164(5):1511–8.
IV. Morice P, Gouy S, Leary A. Mucinous Ovarian Carcinoma. N Engl J Med. 2019;380(13):1256–66.
V. Mackenzie R, Kommoss S, Winterhoff BJ, Kipp BR, Garcia JJ, Voss J, et al. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. BMC Cancer [Internet]. 2015;15(1):1–10. Available from: ???
VI. Bouri S, Simon P, D’Haene N, Catteau X, Noël JC. P53 and PIK3CA Mutations in KRAS/HER2 Negative Ovarian Intestinal-Type Mucinous Carcinoma Associated with Mature Teratoma. Case Rep Obstet Gynecol. 2020;2020:8–11.
VII. Hirst J, Crow J, Godwin A. Ovarian Cancer Genetics: Subtypes and Risk Factors. Ovarian Cancer - From Pathog to Treat. 2018;(May 2019).
VIII. Wai DCC, Shihab M, Low JKK, Mackay JP. The zinc fingers of YY1 bind single-stranded RNA with low sequence specificity. Nucleic Acids Res. 2016;44(19):9153–65.
IX. Meliala ITS, Hosea R, Kasim V, Wu S. The biological implications of Yin Yang 1 in the hallmarks of cancer. Theranostics. 2020;10(9):4183–200.
X. Hosea R, Hillary, Sharon, Wu S. Targeting Transcription Factor YY1 for Cancer Treatment : Current Strategies and Future Directions. 2023;
XI. Matsumura N, Huang Z, Baba T, Lee PS, Barnett JC, Mori S, et al. Yin Yang 1 modulates taxane response in epithelial ovarian cancer. Mol Cancer Res. 2009;7(2):210–20.
XII. Hada T, Miyamoto M, Ishibashi H, Matsuura H, Sakamoto T, Kakimoto S, et al. Survival and biomarker analysis for ovarian mucinous carcinoma according to invasive patterns: retrospective analysis and review literature. J Ovarian Res. 2021;14(1):1–12.
XIII. Rampersad AC, Wang Y, Smith ER, Xu X. Menopause and ovarian cancer risk : mechanisms and experimental support. Am J Clin Exp Obs Gynecol. 2015;2(1):14–23.
XIV. Rojas V, Hirshfield KM, Ganesan S, Rodriguez-Rodriguez L. Molecular characterization of epithelial ovarian cancer: Implications for diagnosis and treatment. Int J Mol Sci. 2016;17(12).
XV. Ryland GL, Hunter SM, Doyle MA, Caramia F, Li J, Rowley SM, et al. Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors. Genome Med [Internet]. 2015;7(1):1–12. Available from:
http://dx.doi.org/10.1186/s13073-015-0210-y
XVI. Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K, Amarasinghe KC, et al. The molecular origin and taxonomy of mucinous ovarian carcinoma. Nat Commun. 2019;10(1):1–11.
XVII. Erickson BK, Conner MG, Landen CN. The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol [Internet]. 2013;209(5):409–14. Available from:
http://dx.doi.org/10.1016/j.ajog.2013.04.019
XVIII. Piek JMJ, Van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJJ, Menko FH, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001;195(4):451–6.
XIX. Przybycin CG, Kurman RJ, Ronnett BM, Shih IM, Vang R. Are all pelvic (Nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol. 2010;34(10):1407–16.
XX. Qian S, Wang W, Li M. Transcriptional factor Yin Yang 1 facilitates the stemness of ovarian cancer via suppressing miR-99a activity through enhancing its deacetylation level. Biomed Pharmacother [Internet]. 2020;126(March):110085. Available from: https://doi.org/10.1016/j.biopha.2020.110085
XXI. Sarvagalla S, Kolapalli SP, Vallabhapurapu S. The Two Sides of YY1 in Cancer: A Friend and a Foe. Front Oncol. 2019;9(November):10–3.